Drug Sponsors

Amarantus, RBCC target NuroPro Parkinson's diagnostic for joint venture

Wednesday, October 10, 2012 11:03 AM

Amarantus BioSciences, a Sunnyvale, Calif.-based biotech focused on brain-related disorders including Parkinson's disease and traumatic brain injury (TBI), and Rainbow Coral (RBCC), a biotech subsidiary Rainbow BioSciences, have selected NuroPro, Amarantus' Parkinson's disease blood test in development, as the target product candidate for the proposed joint venture.

More... »

Takeda to acquire LigoCyte Pharmaceuticals

Friday, October 5, 2012 02:31 PM

Osaka, Japan-based Takeda Pharmaceutical’s wholly-owned subsidiary Takeda America Holdings will acquire LigoCyte Pharmaceuticals of Bozeman, Mont., for an upfront payment of $60 million, with future contingent consideration based on the progress of development projects.

More... »

KaloBios files registration statement for proposed IPO

Friday, October 5, 2012 02:25 PM

South San Francisco-based KaloBios Pharmaceuticals has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

More... »

CollabRx partners with Life Technologies in molecular diagnostics

Friday, October 5, 2012 08:00 AM

CollabRx, a provider of cloud-based expert systems to inform health care decision-making, has formed a multi-year partnership agreement with Life Technologies, global biotechnology tools company for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologies' global cancer diagnostics development and its laboratory developed test services business.

More... »

Takeda, Advinus initiated multi-year drugs discovery collaboration

Thursday, October 4, 2012 02:19 PM

Takeda Pharmaceutical, a Japanese research-based pharmaceutical company, and Advinus Therapeutics, a privately held research-based pharmaceutical company based in India, have entered into an agreement to initiate a three-year discovery collaboration focused on novel targets for major therapeutic areas, including inflammation, CNS and metabolic diseases.

More... »

Epizyme earns $4M in milestones from GSK for novel HMT therapeutics

Thursday, October 4, 2012 11:52 AM

Epizyme, a pharmaceutical company focused personalized therapeutics for cancer, received a $4 million milestone payments from collaborator GlaxoSmithKline based on the achievement of pre-clinical milestones.

More... »

BMS, Sanofi restructure alliance agreement

Thursday, October 4, 2012 10:36 AM

Global biopharmaceutical company Bristol-Myers Squibb and global healthcare company Sanofi have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

More... »

Sanofi to acquire Genfar

Thursday, October 4, 2012 10:04 AM

Global healthcare company Sanofi has signed an agreement to acquire Genfar, a pharmaceuticals manufacturer headquartered in Bogota, Colombia. With this acquisition, Sanofi will expand its portfolio of affordable pharmaceuticals in Latin America.

More... »

Janssen to develop, commercialize Astellas’ ASP015K for immunologic diseases

Wednesday, October 3, 2012 09:52 AM

Janssen Biotech and Astellas Pharma have formed a license agreement whereby Janssen gains the exclusive right to develop and commercialize ASP015K, an Astellas compound, worldwide except for Japan.

More... »

BioInvent focuses its business, reduces staff

Tuesday, October 2, 2012 01:54 PM

Sweden-based BioInvent International has decided to focus its operations with the aim of achieving self-financing of the business before external costs for future new clinical studies. Its development of proprietary antibody drugs will concentrate primarily on developing new cancer drugs, resulting in a clear indication focus. The company currently has five agreements with major companies based on products from the antibody library, n-CoDeR. It will increase the efforts to create new n‑CoDeR agreements for clinical programs and continue to develop existing partnerships.

More... »